Fintel reports that on February 19, 2025, Baird downgraded their outlook for Bio-Techne (NasdaqGS:TECH) from Outperform to ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Bio-Techne (TECH) announced the launch of an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology ...

Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance ...

Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral ...

Baird analyst Catherine Ramsey Schulte downgraded Bio-Techne (TECH) to Neutral from Outperform with a price target of $68, down from $88. The ...

Bio-Techne (NASDAQ:TECH – Get Free Report) was downgraded by stock analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, Ratings reports. They ...

New York State Teachers Retirement System lowered its stake in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 0.2% ...

Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a leading provider of life sciences solutions ...

This was the stock's seventh consecutive day of losses.